Objective-Although hypertension is the most common risk factor for thoracic aortic diseases, it is not understood how increased pressures on the ascending aorta lead to aortic aneurysms. We investigated the role of angiotensin II type 1 receptor activation in ascending aortic remodeling in response to increased biomechanical forces using a transverse aortic constriction (TAC) mouse model. Approach and Results-Two weeks after TAC, the increased biomechanical pressures led to ascending aortic dilatation and thickening of the medial and adventitial layers of the aorta. There was significant adventitial hyperplasia and inflammatory responses in TAC ascending aortas were accompanied by increased adventitial collagen, elevated inflammatory and proliferative markers, and increased cell density attributable to accumulation of myofibroblasts and macrophages. Treatment with losartan significantly blocked TAC-induced vascular inflammation and macrophage accumulation. However, losartan only partially prevented TAC-induced adventitial hyperplasia, collagen accumulation, and ascending aortic dilatation. Increased Tgfb2 expression and phosphorylated-Smad2 staining in the medial layer of TAC ascending aortas were effectively blocked with losartan. In contrast, the increased Tgfb1 expression and adventitial phospho-Smad2 staining were only partially attenuated by losartan. In addition, losartan significantly blocked extracellular signalregulated kinase activation and reactive oxygen species production in the TAC ascending aorta. Conclusions-Inhibition of the angiotensin II type 1 receptor using losartan significantly attenuated the vascular remodeling associated with TAC but did not completely block the increased transforming growth factor-β1 expression, adventitial Smad2 signaling, and collagen accumulation. These results help to delineate the aortic transforming growth factor-β signaling that is dependent and independent of the angiotensin II type 1 receptor after TAC. (Arterioscler Thromb Vasc Biol. 2013;33:2172-2179.)
T horacic aortic aneurysms leading to acute aortic dissections are a common cause of premature deaths in the United States. 1 Hypertension is the most common risk factor for thoracic aortic disease; >75% of patients with thoracic aortic aneurysms or acute aortic dissections have hypertension. 2 Despite the common association of hypertension and thoracic aortic disease, it is not understood how increased pressures on the ascending aorta lead to thoracic aortic aneurysms and aortic dissections. An established model system to study aortic disease is acute angiotensin II (Ang II) infusion in mice, which leads to aortic disease characterized by aortic aneurysm formation and subsequent dissection/rupture in the suprarenal and ascending thoracic aorta. 3, 4 With Ang II infusion, the medial layer of the ascending thoracic aorta thickens with expansion between the elastic lamellae. 4 Additionally, the adventitial fibroblasts secrete proinflammatory cytokines, including interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1), which recruit monocytes to the aortic wall, which further activate fibroblast proliferation and myofibroblast activation, adventitial thickening, and additional cytokine production. 5 Another established mouse model of thoracic aortic aneurysms is the Marfan syndrome mouse, which has been engineered to harbor an Fbn1 missense mutation. Studies in this mouse model have suggested that promiscuous activation of transforming growth factor-β (TGF-β) from stores in the microfibrils in the extracellular matrix drives aortic aneurysm formation. 6 Blocking TGF-β signaling using a TGF-β neutralizing antibody or an Ang II type 1 receptor (AT 1 ) blocking agent, losartan, prevents aneurysms in the Marfan syndrome mouse model. 6 Transverse aortic constriction (TAC), created by contracting the aortic lumen between the innominate artery and the left carotid artery, is a common experimental method to induce pressure overload cardiac hypertrophy and heart failure. Although TAC initially leads to compensatory hypertrophy of the heart, over time the response to the chronic hemodynamic overload becomes maladaptive, resulting in cardiac dilatation and heart failure. 7, 8 Although studies have shown increased aortic diameter and thickening of the aortic wall, the molecular signaling pathways responsible for this remodeling have not been identified with TAC. 8 Evidence of increased TGF-β signaling has been suggested by increased phosphorylated (p) Smad2 levels in medial smooth muscle cells (SMCs). Parallel activation of extracellular signal-regulated kinase (ERK1/2) signaling is also present in this model. Inhibition of both TGFβ and ERK1/2 signaling decreased the extent of aortic dilatation with TAC.
Because Ang II can activate ERK1/2 signaling and increase expression of TGF-β in vascular SMCs, we sought to determine whether signaling through the AT 1 receptor was responsible for both the increased TGF-β and ERK1/2 signaling in the ascending aorta of the TAC mouse model. 8 Our results indicate that inhibition of the AT 1 receptor using losartan significantly attenuated the vascular remodeling associated with TAC but did not completely block the increased TGF-β1 expression, adventitial Smad2 signaling, and collagen accumulation. Thus, these results help to delineate aortic TGF-β signaling that is dependent and independent of the AT 1 receptor after TAC.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

TAC Induces Ascending Aortic Dilatation and Remodeling of the Aortic Wall
Twelve-week-old C57BL/6 male mice were subjected to an established TAC protocol ( Figure IA in the online-only Data Supplement) that reproducibly causes left ventricular hypertrophy. 9 Doppler analysis performed 1 week after TAC demonstrated that the right carotid artery flow velocity ratio was 5-to 10-fold higher than the left carotid artery. 9 Echocardiography identified an increase in the ascending aortic diameter proximal to the aortic band of 23% (±2.5%) in TAC mice compared with sham-operated mice (referred to as controls), similar to the dilatation observed in previous studies ( Figure 1A ). 8 Aortas from the TAC and control mice were harvested with all 3 layers of the aorta preserved (intima, media, and adventitia). Microscopic examination of these aortas revealed no evidence of dissecting aneurysms or intramural thrombus. At 2 weeks after TAC, we measured a significant increase in the thickness of both the adventitia and media of the ascending aorta compared with control aortas ( Figure 1B and 1C). Histomorphometric analysis confirmed increased medial and adventitial area (P<0.05; Figure 1D ). The cell density (total cell number divided by total area) did not significantly change in the medial layer, whereas the adventitial layer had a significant increase in cell density ( Figure 1E ). To further analyze the aortic remodeling with TAC, various components of the ascending aorta were further characterized. Verhoeff-van Gieson staining of elastin showed no elastin fiber fragmentation with TAC ( Figure 2A ). The percentage of elastin content in the medial layer was decreased with TAC, possibly because of the increased medial area or thinning of the elastin fibers (P<0.05; Figure 2B ). Sirius red staining identified increased collagen content in the ascending aorta at 2 weeks after TAC, which was most pronounced in the adventitial layer (P<0.05; Figure 2C ). Medial and adventitial thickness, as well as collagen and elastin content of the descending aorta, did not change after TAC (data not shown).
The cell density of adventitial layer in the ascending aorta increased after TAC when compared with controls. Immunostaining for the nuclear cell mitosis marker, phospho-histone H3 (Ser10) confirmed increased number of proliferating cells in the adventitial layer after TAC (P<0.05; Figure 2D ). The number of cells that express α-smooth muscle actin, a marker for myofibroblasts, was also significantly increased in the adventitial layer after TAC (P<0.05; Figure 2E ). Immunofluorescence using an antibody to fibroblast marker antibody, a marker for fibroblast, was significantly increased in the adventitia after TAC (Figure 2A , bottom). However, the percentage of cells that stained for phospho-histone H3 and α-smooth muscle actin in the medial layer of the ascending aorta did not significantly change.(P>0.05; Figure 2F and data not shown), suggesting that media or accumulation of matrix proteins between the elastin layers. These results suggest that adventitial thickening after TAC is driven in part by myofibroblast proliferation and collagen accumulation. It is notable that these histological changes with TAC are similar to the changes observed in the ascending aortic with Ang II infusion. 3, 4 We have previously shown that Ang II infusion in mice leads to aortic production of IL-6 and MCP-1, which are cytokines that promote vascular inflammation and macrophage recruitment in cooperation with adventitial fibroblasts. 3 Quantitative polymerase chain reaction analysis of RNA harvested from the ascending aortas of TAC and control mice showed a 10-fold increase in IL-6 expression and a 15-fold increase in MCP-1 expression in TAC aortas (P<0.05; Figure 3A ; Figure II in the online-only Data Supplement). Immunostaining of aortic cross-sections from the ascending aorta demonstrated that the levels of IL-6 or MCP-1 were significantly increased in the adventitial and medial layers of TAC aortas compared with controls (P<0.05; Figure 3B ). Macrophage recruitment to the aortas was also confirmed through immunostaining with monoclonal antibodies to CD68 and macrophage/ and monocyte antibody monoclonal, and positively stained cells were detected predominantly in the adventitial layer ( Figure 3C ). Inflammatory cells produce proteases, 5 and Mmp2 and Mmp9 expressions were increased by 10-and 9-fold, respectively, in TAC mice as compared with controls (P<0.05; Figure 3D ). Therefore, a local inflammatory response occurs in the ascending aorta after TAC that is similar to that observed with Ang II infusion. 
Inhibition of AT 1 Activation Attenuates Remodeling of the Aorta With TAC But Does Not Completely Block TGF-β1 Expression and Adventitial Smad2 Signaling
Because pressure-induced remodeling of the ascending aorta leads to histological changes similar to those observed with Ang II infusion, we sought to test the hypothesis that this remodeling is driven by the activation of AT 1 receptor by treating the TAC mice with the AT 1 blocker losartan. 6 The losartan was administered by oral at a dose of 0.6 g/L in drinking water for 3 days before TAC, and mice were continued on oral therapy for 2 weeks after TAC. 6 Doppler analysis demonstrated that there was no statistical difference in arterial flow velocity ratios between TAC animals in the treatment or placebo groups. Echocardiograms also showed that systolic flow velocities in the ascending aortas of TAC mice were 4.9-to 5.3-fold higher than those of sham-operated mice with or without losartan treatment. Systolic flow velocities in the ascending aortas of mice in the losartan treated and placebo groups were not significantly different ( Figure IB in the online-only Data Supplement). Echocardiography revealed that losartan treatment attenuated ascending aortic dilatation associated with TAC ( Figure 4 , upper right side). Morphological and histological analysis revealed that losartan treatment also significantly attenuated ascending aortic wall thickness, medial hypertrophy, adventitial cellular hyperplasia, and collagen accumulation but did not block these histological changes completely ( Figure 4 ). Losartan also significantly reduced the induction of Mcp1, IL6, Mmp2, and Mmp9 expression in TAC ascending aortas ( Figure 3A and 3D; P<0.05). Inflammatory responses and macrophage recruitment, as determined by anti-IL6, MCP-1, CD68, and macrophage/and monocyte antibody monoclonal staining, were also dramatically decreased in the adventitial layer of the ascending aorta after losartan treatment ( Figure 3B and 3C) . These data indicate that the inflammatory response after TAC was effectively inhibited when AT 1 receptor activation was blocked with losartan. However, losartan did not completely inhibit aortic enlargement or medial and adventitial thickening.
Because losartan treatment with TAC attenuated but did not completely prevent adventitial hyperplasia and collagen accumulation, we sought to determine whether TGF-β signaling independent of AT 1 activation could be responsible for these changes. Tgfb2 (TGF-β2) expression increased with TAC, and this increase was effectively blocked by losartan treatment. However, Tgfb1 (TGF-β1) expression was also induced by TAC, and its expression was attenuated but not completely blocked by losartan ( Figure 5A ). Induction of Col1a1 and Col1a3 expression was also incompletely blocked in the TAC aortas with losartan treatment ( Figure 5B ). Immunoblot analysis showed increased levels of phosphorated (p) Smad2 in the ascending aortas of TAC mice. Immunostaining of ascending aortic tissues detected increased number of nuclear pSmad2positive cells in both the medial and adventitial layers after TAC (as quantitated by percentage of pSmad2-positive cells in media divided by total media area; percentage of pSmad2positive cells in adventitia divided by total adventitia area). Although losartan treatment dramatically decreased nuclear pSmad2 staining in the media, positive pSmad2-staining cells remained significantly more abundant in the adventitia in comparison with sham-operated controls ( Figure 5D; P<0.05) . These observations suggest that residual Tgfb1 expression and adventitial Smad2 signaling independent of AT 1 receptor activation may account for some of the aortic histopathologic changes induced by TAC.
Activation of AT 1 Receptor With TAC
Previous studies have demonstrated that losartan attenuated both canonical (Smad dependent) and noncanonical (predominantly ERK1/2) TGF-β-signaling cascades in a TGF-β-and AT1 receptor-dependent manner. 10 To further characterize signaling through the AT 1 receptor with pressure-induced aortic remodeling in mice, ascending aortic tissue was harvested 2 weeks after TAC, and Agtr1a (encoding AT 1 receptor) expression was measured by quantitative polymerase chain reaction. Agtr1a message levels were elevated 3-fold 2 weeks after TAC in comparison with controls ( Figure 5E ; P<0.05). Inhibition of AT 1 signaling by losartan treatment significantly decreased Agtr1a message levels in the TAC ascending aortas to levels similar to controls ( Figure 5E; P<0.05) . To determine the effect of mechanical stress induced by TAC on the activation of ERK1/2, a kinase that can be activated by AT 1 , immunoblotting was performed with antiphospho (p) ERK1/2 antibody. 7 TAC significantly increased pERK1/2 levels in ascending aortic tissue, and this activation was significantly attenuated by losartan ( Figure 5F; P<0.05) .
Increased production of reactive oxygen species (ROS) via NAD(P)H oxidase has been shown to occur with ascending aortic aneurysm formation after Ang II infusion. 3 To determine whether ROS are increased in aortic SMCs in response to TAC, we performed in situ dihydroethidium staining using frozen ascending aortic sections from TAC and control animals. Dihydroethidium is an ROS-sensitive nuclear dye. 3 Widespread and enhanced DHE staining was observed in the TAC ascending aortic regions compared with controls ( Figure IIIA in the online-only Data Supplement). The intensity of DHE staining was significantly attenuated in TAC mice after losartan treatment and reduced to levels similar to control. Cyba (encoding p22-PHOX) encodes the α subunit of cytochrome b(-245), which is a component of the NAD(P)H oxidase that is markedly upregulated after Ang II infusion. 11 Cyba expression was increased in TAC aortas compared with controls ( Figure IIIB C, Immunoblots using antibodies against phosphorylated (p) Smad2 and GAPDH proteins. Lysates were prepared from ascending aortas of sham-operated mice, TAC mice, and TAC mice treated with losartan. n=5 per group. D, Immunostaining for representative crosssections of ascending aorta stained with anti-pSmad2 antibody from sham-operated mice, TAC mice, and TAC mice treated with losartan (low and high magnification separately for each). Arrow indicates nuclear antipSmad2 staining in cells. Dashed line indicates the boundary between media and adventitia. Below bar graphs represent the quantification of the adventitial and medial nuclear pSmad2-positive area from sham-operated mice (white bar), TAC mice (black bar), and TAC mice treated with losartan (gray bar; n=5 per group) separately. *P<0.05. E, Agtr1a expression by Q-PCR analysis in ascending aortic tissues from sham-operated mice (white bar), TAC mice (black bar), and TAC mice treated with losartan (gray bar). Gene expression levels were normalized to Gapdh (n=5 per group). *P<0.05. F, Effect of TAC and losartan treatment on phosphorylated extracellular signal-regulated kinase 1/2 (pERK1/2) levels. Left, Immunoblots using antibodies that recognize pERK1/2 and total ERK1/2 proteins. Immunoblots were prepared using antibodies that recognize pERK1/2 and total ERK1/2 proteins and lysates from ascending aortas of sham-operated mice, TAC mice, and TAC mice treated with losartan. Western blot signals were quantified by densitometry, and the ratio of p-ERK/ERK was calculated (mean+SEM; n=5 per group) and shown by bar graphs. *P<0.05. increased in the ascending aorta after TAC and are reduced by losartan, supporting the hypothesis that AT 1 receptor activation is central to the pathological changes that occur after TAC.
Discussion
Aortic remodeling after TAC is characterized by medial thickening, adventitial hyperplasia, and collagen deposition. 12 In this study, we demonstrate that TAC leads to inflammatory changes in the ascending aorta that are similar to those observed with Ang II infusion, including increased expression of Il6 and Mcp1 and macrophage accumulation. 3, 5 Furthermore, our data also indicate that an AT 1 receptor antagonist, losartan, effectively blocked these TAC-induced inflammatory changes. Because the observed inflammatory changes are similar to those associated with Ang II infusion and were effectively blocked by losartan treatment, these data support the conclusion that losartan effectively blocked AT 1 signaling associated with TAC. Despite this evidence of effective AT 1 blockade on TAC-induced inflammatory responses, other features of aortic remodeling associated with TAC were attenuated but not completely blocked with losartan treatment, including increased lumen diameter and thickening of the medial and adventitial layer. It is important to note that the dose of losatan used in this study was comparable to the dose used in other studies investigating the role of AT 1 receptor in mice. 6, [13] [14] [15] Therefore, this model provides insight into AT 1 -dependent and independent aortic remodeling with TAC.
Our results indicate that Tgfb1 expression was attenuated but not completely blocked by losartan treatment. Similarly, molecular changes downstream of TGF-β signaling, such as myofibroblast proliferation and activation, Col1a1 and Col3a1 expression, adventitial collagen accumulation, and nuclear pSmad2 accumulation, were attenuated but not completely blocked by losartan. Induction of Tgfb2 expression and pSmad2 accumulation in the media were both effectively blocked by losartan, suggesting that these components of TGF-β signaling are dependent on AT 1 activation. Activation of α-smooth muscle actin expression is an important marker of myofibroblast differentiation, which contributes to vascular remodeling through cell proliferation, cell migration, and synthesis of extracellular matrix proteins. 8, 16 Our data suggest that TAC-induced TGF-β1 expression and activation in adventitial fibroblasts may be responsible for myofibroblast differentiation, activation, and fibrosis in the adventitia that is independent of AT 1 activation. It is important to note that losartan did attenuate adventitial myofibroblast activation and collagen deposition. Our data show that losartan may attenuate Ang II-driven monocyte recruitment and previous studies have shown that monocytes help drive fibroblast proliferation, myofibroblast activation, adventitial thickening, and cytokine production. 3, 5 Because losartan effectively blocked monocyte recruitment with TAC, this monocyte-driven component of myofibroblast activation was most likely blocked.
The observed AT 1 -independent, pressure-induced fibroblast to myofibroblast transition after TAC is similar to a well-characterized transition in response to mechanical stress. TGF-β1 is synthesized as a propeptide that binds to the latent TGF-β1-binding protein-1, which is part of the extracellular matrix. Transmission of forces on cell via integrin receptors leads to release and activation of latent TGF-β1 in the extracellular matrix, 17 and the released TGF-β1 promotes the differentiation of fibroblasts to myofibroblasts. Therefore, AT 1 -independent myofibroblast transition and collagen deposition in the adventitial layer with TAC could result from locally increased TGF-β1 attributable to mechanical stress on the aortic wall. Increased expression of Tgfb1 was also identified in the aorta after TAC. The autocrine production of TGF-β by myofibroblasts has been shown to be important for proper wound healing, and the biomechanical forces could also increase autocrine production of TGF-β1. 18 The remodeling of vein grafts driven by increased hemodynamic stress is also characterized by increased Tgfb1 expression and myofibroblast activation in the adventitial layer. 19 Previous studies have shown that TGF-β-mediated ERK1/2 activation is the predominant driver of aneurysm progression in Marfan syndrome. 10 ERK1/2 activation occurs after TAC, but we did not determine whether this activation is driven by AT 1 versus TGF-β signaling. We did show that losartan effectively blocks TAC-induced ERK1/2 activation and nuclear pSmad2 accumulation in medial SMCs. Further studies are needed to determine whether ERK1/2 signaling is attributable to AT 1 activation or downstream of AT 1 -driven TGF-β signaling. It is notable that exposure of SMCs to Ang II leads to rapid EKR1/2 activation. 20 At the same time, Ang II increases TGF-β expression in SMCs, and Ang II can also lead to Smad signaling that is not dependent on TGF-β. 21, 22 Our data indicate that activation of the AT 1 receptor is responsible for many aspects of aortic remodeling induced by TAC. However, the molecular mechanism by which the AT 1 receptor is activated by increased-intraluminal pressure is unknown. AT 1 is a G-protein-coupled receptor. The β-arrestins (β-arrestin-1 and -2) function to regulate agonist-mediated G-protein-coupled receptor signaling by mediating both receptor desensitization and resensitization processes. Recent work suggests that load-induced membrane stretch on cardiomyocytes activates AT 1 receptor signaling in a ligand-independent manner. 23 This ligand-independent activation of the AT 1 receptor occurs via transient receptor potential channels that depend on G protein coupling and the recruitment of β-arrestin to act as a biased agonist for the AT 1 receptor. Mechanical stretch of cardiomyocytes also increases inward potassium currents, by ligand-independent mechanical activation of AT1 receptors. 24 Therefore, the ligand-independent activation of the AT 1 receptor after TAC could result from a similar mechanical activation attributable to the increased mechanical forces induced by the increased pulsatile stretch on aortic SMCs. Alternatively, the increased mechanical stress on SMCs could induce ROS formation and increase the sensitivity of SMCs to Ang II activation. 3 AT 1 activation could potentially further increase ROS production and AT 1 activation in a feedback loop. Finally, local production of Ang II attributable to mechanical stretch may be augmented by increased SMC expression of renin-angiotensin pathways genes.
In summary, this study indicates that AT 1 receptor activation plays a critical role in the ascending thoracic aortic remodeling that occurs because of increased biomechanical stress associated with TAC ( Figure IV in the online-only Data Supplement). This study also illustrates that pressure-induced aortic remodeling involves increased expression of Tgfb1 and Tgfb2, as well as activation of pSmad2. Activation of these TGF-β signaling components is dependent on AT 1 receptor activation in the media but occurs partially independently of AT 1 receptor activation in the adventitia. Furthermore, we have identified histopathologic and molecular changes in the medial versus the adventitial layer of the aorta that are differentially dependent on AT 1 activation. These findings have important implications for understanding the role of AT 1 and TGF-β signaling in the aorta with increased pressures.
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